Candel Therapeutics (CADL) Operating Income (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Operating Income data on file, last reported at -$15.8 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Income fell 93.49% year-over-year to -$15.8 million; the trailing twelve-month figure through Dec 2025 stood at -$48.3 million (down 44.63% YoY), and the FY2025 full-year result was -$48.3 million, down 44.63% from the prior year.
• Operating Income retreated to -$15.8 million in Q4 2025, from -$13.2 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$4.7 million in Q1 2021 to a low of -$15.8 million in Q4 2025.
• A 5-year average of -$9.0 million and a median of -$8.8 million in 2022 frame the typical range for Operating Income.
• Across the five-year window, Operating Income slumped 192.07% in 2021 and advanced 21.1% in 2024, its largest moves.
• Tracing CADL's Operating Income over 5 years: stood at -$7.7 million in 2021, then slipped by 4.66% to -$8.1 million in 2022, then fell by 27.37% to -$10.3 million in 2023, then climbed by 21.1% to -$8.1 million in 2024, then plunged by 93.49% to -$15.8 million in 2025.
• Business Quant data shows CADL's Operating Income at -$15.8 million in Q4 2025, -$13.2 million in Q3 2025, and -$11.2 million in Q2 2025.